Robert Myles Elfont
Profile
Robert Myles Elfont worked as the Chief Medical Officer at Aimmune Therapeutics, Inc. before pursuing his education.
He received an undergraduate degree from the University of Pennsylvania and graduate and doctorate degrees from the University of Rochester Medical Center.
Former positions of Robert Myles Elfont
| Companies | Position | End |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Robert Myles Elfont
| University of Pennsylvania | Undergraduate Degree |
| University of Rochester Medical Center | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Stock Market
- Insiders
- Robert Myles Elfont
